Rock-bottom prices don't always mean rock-bottom businesses. The stocks we're examining today have all touched their 52-week ...

The past year hasn't been kind to the stocks featured in this article. Each has tumbled to their lowest points in 12 months, ...

The holidays might be over, and now the bills are coming due. From credit cards to drained savings, you may feel stuck in a financial hangover. Judy Herbst, the executive director of Savvy Ladies, ...

You got laid off. Now what? Proven steps to bounce back financially and professionally Losing your job is never easy. Being laid off is a significant life event that can trigger a range of emotions ...

XRP has had a volatile year, and a rough second half. Big catalysts like new exchange-traded funds haven't done much for the price. But, over time, work to upgrade network's capabilities likely will.

It's not looking too good for the biotech.

XRP lost its luster after its closely watched SEC lawsuit ended. The government shutdown also likely delayed its spot price ETF approvals. It could bounce back next year as some new catalysts kick in.